News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News UK must draw up post-Brexit pharma strategy Big pharma could take its money elsewhere post Brexit, report warns.
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
News Big pharma could leave UK - AZ's Pangalos Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
Debates & Insight Sponsored Finding a cure: Getting the best Brexit deal for Britain’s l... Four months have now elapsed since the UK voted to leave the EU.
News UK aims to cut four years from drug development process NICE, regulator and NHS should work together, according to review.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
